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Abstract 
Synthesis of the first water-soluble porphyrin radiolabeled with fluorine-18 is described; a new 
molecular theranostic agent which integrates the therapeutic selectivity of photodynamic 
therapy (PDT) with the imaging efficacy of positron emission tomography (PET). Generation 
of the theranostic was carried out through the conjugation of a cationic water-soluble porphyrin 
bearing an azide functionality to a fluorine-18 radiolabeled prosthetic bearing an alkyne 
functionality through click conjugation, with excellent yields obtained in both cold and hot 
synthesis. Biological evaluation of the synthesised structures shows both the first example of 
an 18F-radiolabeled porphyrin retaining photocytotoxicity following radiolabeling, as well as 
demonstrable conjugate uptake and potential application as a radiotracer in vivo. The promising 
results gained from biological evaluation demonstrate the potential of this structure as a 
clinically-relevant theranostic agent, offering exciting possibilities for the simultaneous 
imaging and photodynamic treatment of tumours. 
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Introduction 
A growing interest in the development of theranostics and “personalised medicine” 
highlights the utility of dual-functional theranostic compounds, which combine diagnostic and 
therapeutic modalities within the same agent, for the treatment of neoplastic conditions. 
Therapeutic strategies exploited to date include nucleic acid delivery, chemotherapy, 
hyperthermia (photo-thermal ablation), photodynamic therapy, and radiation therapy, coupled 
with imaging strategies including MRI, fluorescent markers, single-photon emission computed 
tomography (SPECT), and positron emission tomography (PET).1 
Porphyrins offer excellent potential as theranostic agents for personalised medicine; their 
potent cytotoxic activity within the field of photodynamic therapy has been well documented,2 
demonstrating their increasing clinical relevance in these treatment modalities.3–5 In addition, 
porphyrins demonstrate potential as imaging agents from the inherent fluorescence of the 
tetrapyrrolic core, and also their ability to chelate metals suitable for PET, SPECT and MRI 
(see Boyle et al.2 for a comprehensive review). PET in particular offers quantitative imaging 
of physiological and pathophysiological activities in vivo and is well-suited for oncology and 
whole body imaging.6 
Some progress has been made towards functionalising PDT agents with positron-emitting 
radionuclides for use in PET; however, to date the vast majority of radiolabeling strategies 
have utilised porphyrins as chelating agents for radioisotopes such as 64Cu,68/67Ga, 140Nd and 
166Ho7–12 (see Waghorn et al.13 for a  comprehensive review of radiolabeled porphyrins).  
Unfortunately, this strategy can inhibit the therapeutic potential of the porphyrin 
photosensitiser, as chelation of paramagnetic isotopes quench the photocytotoxic action of the 
porphyrin, rendering it useless as a therapeutic agent. These limitations encouraged us to 
investigate the attachment of non-metal positron emitting radionuclides onto photodynamically 
active porphyrins. 
Fluorine-18 is often referred to as the “radionuclide of choice” for PET imaging agents. The 
109.8 minute half-life permits the use of multistep synthesis and allows ample time for 
transportation to the clinic, whilst the high proportion of positron decay and relatively low 
energy of emitted positrons/positron range facilitate high resolution PET imaging. Despite this, 
examples of porphyrins and other tetrapyrrolic photosensitisers radiolabeled with fluorine-18 
in the literature are limited. While methods for fluorine-18 radiolabeling of a porphyrin14  and 
a phthalocyanine15 have been described, neither of these methods are ideal; both require 
extended reaction times and harsh reaction conditions, with radiochemical yields of less than 
25% achieved. In addition, neither demonstrated retention of the cytotoxic action of the 
photosensitiser following radiolabeling. 
Following our current interest in porphyrin bioconjugation using the Copper (I) –Catalysed 
Alkyne-Azide Cycloaddition (CuAAC) reaction16–18, it was rationalised that a click 
conjugation methodology could be utilised to radiolabel a porphyrin under mild reaction 
conditions, providing a mild and high yielding method for radiolabeling water-soluble 
porphyrins with minimal impurities.19 
 
Results and Discussion 
The requirement that we considered essential for designing a porphyrin-fluorine-18 labeled 
theranostic agent was that it should combine the activity of both a radiotracer and a 
photocytotoxic therapeutic agent. Additionally, the half-life of the chosen radionuclide dictated 
that the synthesis be quick and facile, while offering a simple but efficient purification. The 
agent was required to be water-soluble, to allow administration without complex formulation. 
To date, there have been no reports of fluorine-18 labeled porphyrins exhibiting these 
requirements.  
Our synthetic route (Scheme 1) utilized a water-soluble cationic porphyrin bearing an azide 
clickable moiety, and a PEG chain bearing an alkyne clickable moiety. The fluorine labeled 
PEG chain was then clicked to the porphyrin by CuAAC reaction to afford the product. 
 
Porphyrin Synthesis and Characterization  
 
Porphyrin 2 was obtained from the hydrolysis of porphyrin 1 according to a previously 
published procedure20 in 75 % yield.  Subsequent synthesis of porphyrin  317 was accomplished 
by diazotization of the amine precursor, with 3 obtained in a yield of 97 %. Methylation to 
produce porphyrin 4 was carried out with methyl iodide to produce the water-soluble, cationic 
pyridiniumyl porphyrin 421 giving a 90 % yield, with ammonium 
hexafluorophosphate/tetrabutylammonium chloride workup carried out to facilitate anion 
substitution and product purification.18 
 
At this stage, zinc chelation of the porphyrin was required to prevent complexation of the 
copper catalyst used in the click reaction by the free base porphyrin. While chelation of the 
paramagnetic copper catalyst can both interfere with the CuAAC reaction, and quench any 
PDT effect of the porphyrin, similar zinc chelated porphyrins have been shown to resist copper 
metallation and also demonstrate potent photocytotoxicity22.  
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Scheme 1. (a) propionic acid, 180 ºC 1 hr, (b) 12 M HCl 100 ºC 3 hr, then DCM/TEA 9:1 10 
min,(c) NaNO2 soln. and TFA at 0 ºC 15 min, then NaN3 soln. added 0 ºC 1 hr (d) CH3I in 
DCM 40 ºC 18h, counter-ion exchange NH4PF6 and TBAC, (e) Zn(OAc)2 in water  rt 30 mins, 
then counter-ion exchange NH4PF6 and TBAC. 
Functionalized PEG Chain Synthesis and Characterization  
Two examples of heterobifunctional tetraethylene glycol chains were synthesized to act as 
carriers for 18F, both functionalized with alkyne groups to allow facile click conjugation to the 
photosensitiser. The tetraethoxy PEG chain was selected as a synthetic target due to the low 
volatility and excellent amphiphilicity of this structure making it an ideal target for safe and 
biocompatible radiolabeling. While 7 was produced with a tosyl group for radiolabeling via 
substitution with fluorine-18, fluorine-functionalized 8 was utilized both for radiolabeling via 
isotopic substitution and for cold cytotoxicity studies.    
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Scheme 2. (a) NaH in THF at -20 ºC. Propargyl bromide at rt 18h under N2, (b) TsCl, TEA, 
DCM. N2 rt 17 h, (c) anhydrous THF under argon, 80 ºC,1 M TBAF in THF. 
  
 Synthesis of 6 from (OH-PEG5-OH) was carried out according to a literature procedure23 to 
yield 68 % as a pale yellow oil. Tosylation was then carried out24 to produce 7 in 80 % yield. 
The synthesis of 8 was initially performed using 19F in the form of TBAF, with TLC monitoring 
showing almost instantaneous generation of 8 from 7 in 90% yield, with product identity 
confirmed by NMR and MS. 
 
 8 
Click Conjugation of Porphyrin and Functionalized PEG Chain 
To afford synthetic flexibility, initially, click conjugation of 7 and 8 to porphyrin 5 was 
attempted, with the aim of producing a porphyrin which could undergo radiolabeling in a one-step 
process. However, this direct labelling methodology was found to be unsuitable for two reasons; 
in the presence of a source of fluoride ions porphyrin 5 was found to undergo counter ion exchange 
on the pyridiniumyl cationic moieties, producing a product with poor water-solubility and labile 
fluoride which could easily dissociate in vivo. Secondly, it was found that under the described 
conditions, the tosylated PEG chain did not undergo the click reaction. As a result, click 
conjugation was then carried out utilising chain 8 only, allowing both cold optimisation of the 
click methodology, as well as production of a cold standard of porphyrin conjugate 9 for both 
analysis and biological evaluation (Scheme 3).  
Conjugate 9 was synthesized by CuAAC reaction. In contrast to the tosylated chain 7, 8 was 
found to undergo rapid and high-yielding click conjugation under the described conditions, 
affording the product 9 in excellent yield (90%). Reaction progress was monitored by both TLC 
and HPLC; the developed HPLC methodology also provided good separation between the 
precursors and final product, allowing for semi-preparative HPLC purification to isolate the 
radiolabeled product.  
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Scheme 3. Copper (II) sulfate, sodium ascorbate and TBTA in 1:3 THF: MW 40 ºC, 60W, 15 min. 
 
18F labelling of PEG Chain  
Generation of the radiolabeled prosthetic group 8[18F] was achieved via  (Scheme 4 nucleophilic 
substitution of the tosyl group. Initially,  reaction of dried fluorine-18 with chain 8 was 
investigated. 
TsO
O
O
O
O
7
18F
O
O
O
O
8[18F]
 
Scheme 4. (a) dried 18F, 140 ºC, 10 min. (b) dried 18F, 180 ºC, 10 min. 
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8 was heated with dry 18F at 180 ºC for 10 minutes, giving an expected low incorporation of 4.48 
% ± 1.37 (n = 3) 18F (Figure 1), ), with increased heating times showing no significant variation. 
Nucleophilic substitution of 7 demonstrated excellent 18F labelling, with heating for 10 minutes at 
140 ºC resulting in a 93.4 % ± 3.34 (n = 3) radiochemical yield (Figure 2).  
 
Figure 1.  RadioTLC of the isotopic substitution reaction, showing <5% incorporation. Region 1: 
free 18F, Region 2: incorporated 18F 
 
Purification of 8 from the precursor 7 was carried out on Sep-Pak®Light tC18 cartridges, to 
remove residual free 18F, with the product obtained in >99% radiochemical purity. Alternatively, 
generation of the a carrier-added derivative was found to be possible, with residual 7 reacted with 
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TBAF to produce a 19F/18F mixture, giving a single chemical product with no reduction in 18F 
incorporation observed.  
 
Figure 2.  RadioTLC of the substitution reaction, showing >95% incorporation (left) and >99% 
radiochemical purity following purification (right).  
Radiolabeled porphyrin conjugate synthesis and characterisation 
As previously discussed, under click conditions chain 8 demonstrates excellent conjugation 
yields with porphyrin 5, while the precursor 7 shows no reaction with the same porphyrin. 
Conveniently, click reaction of mixtures of both 7 and 8 with porphyrin 5 were also found to yield 
porphyrin 9 exclusively, and therefore no HPLC purification of the mixture was required.  
CuAAC reaction of the photosensitiser 5 with the radiolabeled chain 8[18F] was performed by 
heating at 40 ºC for 20 minutes under previously described conditions. The mixture was purified 
on a Sep-Pak® Light tC18 cartridge and washed several times with water before the product was 
eluted with ethanol. Incorporation yields of final product 9[18F] were 34.2 % ± 2.46 (n = 3) (Figure 
3). 
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Figure 3. RadioTLC of click reaction; 32.8% incorporation of fluorine-18 within 9[18F] (Region 
1). 
Evaluation of cytotoxicity 
Confirmation of the potential of conjugate 9 as a therapeutic agent was carried out through the 
evaluation of the photocytotoxicity of the conjugate in a human adenocarcinoma (HT-29) cell line. 
Irradiation of 9 was carried out using an Oriel light system filtered to remove light below 550 nm, 
 13 
and the results were compared to a non-irradiated control. The irradiated light chosen aligns well 
with the two Q-bands of the zinc chelated porphyrin, while excluding the Soret band, giving results 
which would be applicable to both in vivo testing and clinical use. Human colon adenocarcinoma 
cells (HT-29) were incubated for 1 hr with increasing concentrations of 9, and irradiated with light 
(> 550 nm) giving an LD90 of approximately 1 x 10-4 M (Figure 4), with minimal dark toxicity 
(>75 % cell survival), observed for all non-irradiated conditions.  
 
Figure 4. Graph of cytotoxicity assay. Assay was carried out on HT-29 cell lines, with results 
displayed for conjugate 9 following irradiation (IRR) and non-irradiated control (NI). 
   
Fluorescence and bright field images (Figure 5) of photosensitizer accumulation in the HT-29 
cell line were also acquired, demonstrating cellular uptake of the photosensitizer in this cell line. 
The bright field image also exhibits blebbing around the cell membrane, indicating rapid onset 
apoptosis due to photosensitizer activation by the excitation source of the microscope, behaviour 
which has previously been reported for cationic porphyrins.25  
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Figure 5. (Top Image) Fluorescence image showing cellular uptake of photosensitizer 9 in human 
adenocarcinoma (HT-29) cells, (Bottom Image) Bright field image of HT-29 cells incubated with 
9. 
 
In vivo radiochemistry 
Preparation of the 8[18F] and subsequent click reaction to form conjugate 9[18F] was performed as 
described in the experimental, with both crude  8[18F] and 9[18F] purified by semi-preparative 
HPLC after each stage of the reaction. Fluorination of 8[18F] was carried out in acetonitrile, to 
yield the product in 77 % RCY (non-decay corrected) and >99% RCP by HPLC. Click reaction to 
 15 
the porphyrin was then carried out at 60°C to produce 9[18F] in 16 % RCY (non-decay corrected) 
and >97 % RCP by HPLC. The isolated sample of 9[18F] demonstrated good specific activity of 
1GBq/µmol, with an obtained log P value of -2.48 (PBS:octanol).  
 
Figure 6 .  RadioTLC of the nucleophilic substitution synthesis of 8[18F], showing >75 % 
incorporation. 
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Figure 7. RadioTLC of click reaction synthesis of 9[18F], with over 66% incorporation 
demonstrated. 
In vivo evaluation 
Tumour uptake was assessed in the HT29 and U87 xenograft models. Conjugate 9[18F] was 
injected intravenously (i.v.) and biodistribution was quantified by PET imaging (8).  
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Figure 8. Dynamic 9[18F] uptake in tumour bearing animals. A and B: Transaxial and coronal 
image slices centred on the tumour at 80-90 minutes, showing uptake in tumour and liver  in 
representative HT29 tumour (arrows). C, D: Time activity curves of 9[18F] in liver E,F: Time 
activity curves of 9[18F] in tumour and muscle. All time activity curves represent average data 
from four tumour-bearing animals  ±S.E.M. 
As expected,  9[18F] accumulated mainly in the liver (Figure 8 C&D), consistent with previously 
reported data on porphyrins13. There was also evidence of tumour accumulation in both models, 
with average tumour-to-muscle ratios of 1.4 (SUVmean) or 2.3 (SUVmax) at 80-90 minutes 
(Figure 8 E&F).The accumulation of untargeted porphyrins in tumour tissue is thought to be due 
to the enhanced permeability and retention (EPR) effect, and this is assumed to be high in 
preclinical xenograft models26. For the purposes of this study we assessed uptake in HT29 and 
U87 tumours, as these have been reported to to effect low or high levels of EPR mediated 
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nanoparticle accumulation respectively27,28. Tumour uptake was observed in all tumours, 
exhibiting the potential of this theranostic agent for calculating the optimal irradiation time for 
clinical PDT treatment.  
Conclusions 
In conclusion, we have demonstrated that a single theranostic agent in the form of a novel 
fluorine-18 radiolabeled water-soluble porphyrin can be synthesized from an alkyne-bearing 18F 
PEG carrier chain and an azide functionalised porphyrin. This is the first demonstration of an 18F 
radiolabeled porphyrin retaining photocytotoxicity following radiolabeling; with the synthesised 
compound showing cellular uptake, good photocytotoxicity and minimal dark toxicity in a relevant 
human cancer cell line, as well as confirmed uptake of the conjugate into neoplastic tissue and 
demonstrated potential as a radiotracer in vivo. The promising results gained from biological 
evaluation demonstrate the potential of this structure as a clinically-relevant theranostic agent, 
offering exciting possibilities for the simultaneous imaging and photodynamic treatment of 
tumours.  
 
Experimental 
Materials and methods 
1H and 13C NMR spectra were recorded on JEOL Eclipse 400 and JEOL Lambda 400 
spectrometers (operating at 400 MHz for 1H and 100 MHz for 13C). Chemical shifts (δ) are reported 
in parts per million (ppm), referenced to CDCl3 and DMSO. Coupling con- stants ( J) are recorded 
in Hz and significant multiplicities described by singlet (s), doublet (d), multiplet (m). MALDI 
mass spectra were performed by the EPSRC National Mass Spectrometry Facilities, Swansea, UK. 
UV–visible spectra were recorded on a Varian Cary spectrophotometer. Chemical reagents and 
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solvents were purchased from Sigma-Aldrich and Alfa Aesar, and were used as received unless 
otherwise stated. Microwave reactions were carried out in a CEM Discover Benchmate microwave 
reactor controlled using Synergy software. In all cases, maximum stirring, maximum pressure of 
200 bar and 2 minute maximum heating step were used. Reaction temperatures were monitored 
using an external IR probe and carried out in a 10 ml sealed reaction vessel. Irradiation of cells 
during phototoxicity assays was carried out using an Oriel lamp system with a Schott 06515 Long 
Pass Optical Filter, allowing irradiation with 95–98% of light above 515 nm. Fluorine-18 (18F) 
was produced by the 18O(p, n) 18F nuclear reaction using a 7.5 MeV ABT Biomarker Generator 
cyclotron (ABT Molecular Imaging, Inc.©, USA) and [18O]H2O >98% (CMR©, Russia), being 
the current reaching the target ~4.2 µA. Specific activity of the produced 18F was an average of 
100 GBq.mol-1, according to the manufacturer. Analytical HPLC was performed through an 
Agilent 1200 series with a 254 nm UV detector (Agilent Technologies©, USA) and effluent 
radioactivity was monitored using a NaI crystal coupled to a photomultiplier tube (LabLogic 
Systems Limited©, UK). Purification by semi-preparative HPLC was performed through an 
Agilent 1100 series with a 254 nm UV detector (Agilent Technologies©, USA) and effluent 
radioactivity was monitored using a NaI crystal coupled to a photomultiplier tube (LabLogic 
Systems Limited©, UK). An ACE 5 C18 10*250 5A column was used, with all products eluted 
eluted using MeCN:water gradients containing 0.1% TFA (flow rate 4.7 ml/min).  
 
Synthetic procedures 
Synthesis of 4: Methyl iodide (2 ml, 32.3 mmol) was added via syringe to a stirred solution of 
5-[4- azidophenyl]-10,15,20-tri-(4-pyridyl) porphyrin (100 mg, 0.151 mmol) in dimethyl 
formamide (DMF) (10 ml). The reaction was then stirred at 40 ºC overnight. After filtering through 
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cotton wool, the residue was dissolved in water. Ammonium hexafluorophosphate was added, and 
the product filtered. The solid was dissolved in acetone and tetrabutylammonium chloride was 
added, and the mixture filtered. The crude product was precipitated from diethyl ether over MeOH 
to yield a dark brown solid (148 mg, 90%). UV-vis (H2O): max, 424, 520, 562, 590, 648. log (424 
nm) = 5.11 M-1cm-1. 1H-NMR (DMSO-d6): δ 4.74 (s, 9H, CH3),7.65 (d, 2H, 5-m-Ph), 8.28 (d, 
2H,5-o-Ph), 9.01 (m, 6H, 10,15,20-o-Py), 9.12 (m, 8H, βH), 9.07 (m, 6H, 10,15,20-m-Py). 13C-
NMR (DMSO-d6): δ 40.13 (CH3), 114.66, 115.42, 117.63, 122.87, 132.11, 132.25 (β-C), 135.53, 
143.62 (β-C), 147.88, 148.15, 148.35, 150.19, 158.54. MS: (ESI) m/z 351 (100[M -3Cl] 2+), 
HRMS: calcd. For C46H33N10: 351.1478 found 351.1481. 
Synthesis of 5: Porphyrin 4 (10.0 mg 0.0141 mmol) was dissolved in water (10 ml) and zinc(II) 
acetate (3.00 mg, 0.0133 mmol) added. The mixture was stirred at room temperature for 1 hour 
and checked for completion by TLC. Ammonium hexafluorophosphate was added, and the product 
filtered. The solid was dissolved in acetone and tetrabutylammonium chloride was added, and the 
mixture filtered. The crude product was precipitated from diethyl ether over MeOH (10.4 mg, 95 
%). UV-vis (H2O): max, 436, 564, 612. 1H-NMR (DMSO-d6): δ 4.72 (s, 9H, CH3),7.61 (d, 2H, 
5-m-Ph), 8.21 (d, 2H,5-o-Ph), 8.9-9.06 (m, 14H, 10,15,20-o-Py, βH), 9.44 (m, 6H, 10,15,20-m-
Py). 13C-NMR (DMSO-d6): δ 48.26 (CH2-N3), 115.26, 116.03, 118.21, 122.73, 132.13, 132.65(β-
C), 133.70, 136.13, 139.44, 139.87, 144.22(β-C), 148.75, 148.92, 150.75, 159.10. MS: (ESI) m/z 
400 (100[M -2Cl] 2+), HRMS: calcd. For C44H33Cl1N10Zn1 : 400.0929 found 400.0932. 
Synthesis of 6: Tetraethylene glycol (2.70 g, 13.9 mmol) was slowly added to a solution of NaH 
(60 % in mineral oil, 0.8 g, 20 mmol) in THF (20 ml) at -20 ºC. Propargyl bromide (80 % in 
toluene, 1.48 ml, 13.9 mmol) was added after all bubbling stopped and the mixture was stirred 
overnight at room temperature and nitrogen. The mixture was filtered and solvent removed under 
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reduced pressure. The crude was then purified by column chromatography (4.5 % MeOH : DCM) 
to yield the product as a pale yellow oil (1.82 g, 68%). 1H-NMR (CDCl3): δ 2.40 (s, 1H, C≡CH), 
2.92 (OH), 3.52-3.66 (m, 16H), 4.13 (d, 2H, CH2-C).13C-NMR- (CDCl3): δ58.39 (CH2-C), 61.68 
(CH2-OH), 69.13, 70.37, 70.41, 70.56, 70.58, 70.65, 72.61, 74.65 (C≡CH), 79.66 (C≡CH). MS: 
(ESI) m/z 233 (100[M + H]+), HRMS: calcd. for C11H21O5: 233.1384 found 233.1380 
 
Synthesis of 7: TsCl (1.60 g, 8.39 mmol) and TEA  (1.17 ml, 8.39 mmol) were added to a stirred 
solution of PEG 6 (1.86 g, 8.00 mmol) in DCM. The mixture was stirred under nitrogen at room 
temperature for 17 hours. The solvent was removed under reduced pressure and the product 
purified by column chromatography to yield the product as a pale yellow oil (2.47 g, 80 %). 1H-
NMR (CDCl3): δ 2.38 (s, 4H, C≡CH, CH3), 3.45-3.65 (m, 14H), 4.02-4.14 (m, 4H, CH2-C, CH2), 
7.26 (d, 2H, J=7.9 Hz), 7.70 (d, 2H, J=7.1 Hz). 13C-NMR (CDCl3): δ21.57 (CH3), 58.41 (CH2-
C), 68.75, 69.09, 69.40, 70.35, 70.54, 70.66, 70.73, 74.76 (C≡CH), 79.73 (C≡CH), 127.98, 129.93, 
130.37, 132.95 (4-Ar), 144.92 (1-Ar).MS: (ESI) m/z 404 (100[M + NH4] +), HRMS: calcd. For 
C18H30O7N1S1 : 404.1737 found 404.1726. 
 
Synthesis of 8: PEG 7 (2.47 g, 6.40 mmol) was dissolved in 10 ml of anhydrous THF under 
argon. The solution was heated to 80 ºC and a solution of 1 M TBAF in THF (4.84 ml, 4.84 mmol) 
was added. The product was allowed to cool and the solvent was removed under reduced pressure. 
The product was purified by column chromatography using (25 % DCM : ethyl acetate) to give a 
pale yellow oil (1.35 g, 90 %). 1H-NMR (CDCl3): δ 2.40 (s, 1H, C-CH), 3.58-3.68(m, 14H), 4.14 
(d, 2H, O-CH2-C), 4.5, 48 Hz, 4 Hz(dt, 2H, F-CH2). 13C-NMR (CDCl3): δ21.57 (CH3), 58.40 
(CH2-C), 70.39, 70.59, 70.69, 70.78, 74.62(C≡CH), 79.73 , 82.38, 84.05, 128.97 J = 744 Hz(CH2-
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F).19F-NMR (CDCl3): δ 179.50.MS: (ESI) m/z 252 (100[M + NH4] +), HRMS: calcd. For 
C11H23F1O4N1 : 252.1606 found 252.1607. 
 
Synthesis of 9: Porphyrin 5 (10.0 mg 0.0118 mmol) was added to a 10 ml microwave tube and 
PEG 8 (3.00 mg, 0.013 mmol) in THF : water (1 : 3, 8 ml) was added. Copper (II) sulphate 
pentahydrate (5.00 mg, 0.0200 mmol), sodium ascorbate (5.00 mg, 0.0250 mmol) and TBTA (1.00 
mg, 1.90 mmol) were added and the mixture heated to 45 ºC by microwave (75 W, max pressure 
100 bar) for 20 minutes. The mixture was concentrated under reduced pressure and ammonium 
hexafluorophosphate was added. The mixture was filtered and redissolved in acetone. 
Tetrabutylammonium chloride was added and the mixture filtered. The product was precipitated 
from diethyl ether over MeOH to yield the product as a green solid (11.4 mg, 90 %). UV-vis (H2O): 
max, 435, 565, 614 log (435 nm) = 5.03 M-1cm-1. 1H-NMR (DMSO-d6): δ 3.65 (m, 14H), 4.53, 
J=24 Hz,4 Hz (dt,2H, CH2-F),4.72 (s, 9H, CH3), 4.77 (s, 2H, O-CH2-Triazole), 8.34-8.44 (m, 4H, 
5-Ph), 8.85-9.06 (m, 14H, 10,15,20-m-Py, m 8H, βH), 9.20 (s, 1H, Triazole- H), 9.44 (d, 6H, 
10,15,20-o-Py). 13C-NMR (DMSO-d6): δ 40.13, 48.26, 58.05, 64.06, 69.77, 70.44.MS: (ESI) m/z 
333 (100[M -3Cl] 3+), HRMS: calcd. For C55H52 O4N10F1Zn1 : 333.1144 found 333.1152. 
 
 
 
Radiochemistry 
Fluorine production: The fluorine-18 radionuclide was produced by the 18O(p,n)18F reaction on 
an enriched water target. Oxygen-18 water containg 80 MBq of 18F was transferred to a 5ml V-
vial containing potassium carbonate solution in water (0.1M, 200 μl), and Kryptofix K222 (5 ug) 
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in water (300 μl). The water was removed via azeotropic distillation with acetonitrile under a 
compressed air stream at 110 ºC.  
 
Synthesis of 8[18F] via isotopic substitution: To a 5ml V-vial containing the dried 18F was added 
8 (5 mg, 0.021 mmol) in dry DMSO (200 μl) and the mixture heated to 180 ºC for 10 minutes. The 
mixture was diluted with methanol (1 ml) and passed through a Sep-Pak Light Alum N cartridge. 
Labelling yields were determined by radioTLC, and the mixture was used without further 
purification. 
 
Synthesis of 8[18F] from 7: To a 5ml V-vial containing the dried 18F was added  7 (5 mg, 0.013 
mmol) in dry DMSO (200 μl) and the mixture heated to 140 ºC for 10 minutes. The mixture was 
diluted with methanol (1 ml) and passed through a Sep-Pak Light Alum N cartridge. Labelling 
yields were determined by radioTLC, and the mixture was used without further purification. 
 
Synthesis of carrier-added 8[18F]: To a 5ml V-vial containing the dried 18F was added 7 (5 mg, 
0.013 mmol) in dry DMSO (200 μl) and the mixture heated to 140 ºC for 10 minutes. 
Tetrabutylammonium fluoride (5 mg, 0.019 mmol) in dry DMSO (200 μl) was added and the 
mixture heated to 140 ºC for 5 minutes The mixture was diluted with methanol (1.5 ml) and purified 
on a Sep-Pak Light Alum N cartridge. Labelling yields were determined by radio-TLC, and the 
mixture was used without further purification. 
 
General methodology for click reaction 9[18F]: To a 10 ml microwave tube containing 8[18F] 
was added 5 (1 mg, 1.1 μmol) in water (0.2 ml) and a solution of TBTA (174 μg, 0.4 μmol), and 
 24 
copper (II) sulfate pentahydrate (50 μg, 0.2 μmol) and sodium ascorbate (80 μg, 0.4 μmol) in water 
(0.2 ml). The mixture was heated to 40 ºC for 20 minutes (MW, 60 W). The mixture was diluted 
with water (20 ml) and passed through a Sep-Pak Light C18 cartridge. The cartridge was washed 
with water (5 ml) and the product eluted with ethanol (0.5 ml). 
 
in vivo Radiochemistry 
Fluorine production: Oxygen-18 water (~140 μL) containing 1.8 GBq  of 18F was transferred to a 
5 ml V-vial containing potassium hydrogencarbonate solution (0.5 ml, 5 mg/ml) and Kryptofix 
K222 (10.2 mg in 1 ml of dry acetonitrile). The water was removed via azeotropic distillation with 
acetonitrile under a compressed argon stream at 90 ºC. 
Synthesis of 8[18F]: To a 5 ml V-vial containing dried 18F (1.4 GBq) was added 7 (6.7 mg) in dry 
acetonitrile (1 ml) and the mixture heated to 90 °C for 10 minutes. The crude reaction mixture was 
passed through Sep-Pak Light Alum N cartridge. Eluted activity: 982 MBq, (RCY 77%.)  The 
solvent was reduced to ~ 0.2 ml at 90 oC under a compressed argon stream and the residue diluted 
with water (0.5 ml). The crude was purified on semi-preparative HPLC (MeCN:water, 20% to 
30% in 15 min), with  8[18F] eluting at 10-11 min (726 MBq). The collected HPLC fraction was 
diluted to 40 ml with water and loaded on home-made Oasis C18 Lite Sep-Pak cartridge, washed 
with water (10 ml) and eluted with methanol (2 ml). Methanol solution containing activity was 
dried at 60oC.  
Synthesis of  9[18F]: To a 1.7 ml champagne HPLC vial containing pure 8[18F] (446 MBq) was 
added a combined solution of copper (II) sulfate pentahydrate (0.5 mg in 12.5 µl water), sodium 
ascorbate (3.75 mg  in 50 µl water), TBTA (0.5 mg in 160 µl methanol) and porphyrin (0.2 mg  in 
100 µl water). The reaction mixture was heated to 60 °C for 35 minutes. The crude product was 
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purified on semi-preparative HPLC (MeCN:water, 20% to 40% in 30 min) with 9[18F] eluting at 
15-16 min (72.6 MBq, RCY 16.2 %). The fraction was diluted with water and purified on an Oasis 
C18 Sep-Pak cartridge. The product was eluted with ethanol (0.5 ml) while filtering on a 0.22 µm 
filter. The solution was evaporated to dryness under stream of compressed argon at 60oC and 
dissolved in 0.2 uL of heparin-water (33.6 MBq).  
 
Quality control 
All reactions were monitored, and incorporation was determined by radio-TLC using silica TLC 
sheets, in 9:1 DCM/MeOH solution. RCY and RCP was determined  for all compounds using 
analytical HPLC under gradient conditions (MeCN:water with 0.1 % TFA, 25-40 % over 30 mins). 
The compounds were eluted after the following retention times (tR): 8[18F] 8.5 min, 9[18F] 16:6 
min. 
Partition coefficient determination 
9[18F] (3.4 MBq) was partitioned in a mixture of 1 ml of 1-octanol and 1 ml of PBS after being 
vortexed for 5 min. Following centrifugation at >1,200 g for 5 min, the octanol and aqueous phases 
were sampled and counted. Reported log P value is based on the average of three samples.  
PET imaging 
CD-1 nu/nu female mice (Charles River, UK) bearing subcutaneous HT29 or U87 xenografts of  
200-600mm3 were anaesthetised with 1–2% Isoflurane, the tail vein was catheterised and they 
were placed in the Minerve Small-Animal Imaging Cell (Minerve, France) and transferred to the 
SuperArgus 2R preclinical PET/CT scanner (Sedecal, Spain). At the start of the PET acquisition, 
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animals were injected with ~10MBq of 18F-9 intravenously (IV) via the tail vein and 90-minutes 
of data were acquired using the  250-700 keV energy window. Data was histogrammed into 3 x 
120, 1 x 240, 4 x 600 and 2 x 1200-second bins and reconstructed into a 175 x 175 x 61 (0.3875 
x 0.3875 x 0.775mm) matrix using OSEM2D with 16 subsets and 2 iterations and 
randoms/scatter/attenuation correction via Sedecal MMWKS software. The image data was 
normalized to correct for nonuniformity of response, dead-time count losses and radioactive 
decay to the time of injection. Activity concentrations were determined by conversion of count 
rate data from reconstructed images. Regions of interest were drawn around the tumour and 
sections of quadriceps muscle and liver, and time-activity curves generated using AMIDE 
software29 (Loening & Gambhir, Molecular Imaging 2003). CT images were acquired via 360 
projections/8 shots at a tube voltage of 45kV and current of 140µA. Respiration and temperature 
were monitored throughout using the SA Instruments 1025T monitoring system (SA Instruments, 
CA, USA).  All procedures were carried out in accordance with the Animals in Scientific 
Procedures Act 1986 and UKCCCR Guidelines 2010 by approved protocols following 
institutional guidelines (Home Office Project License number 60/4549 held by Dr. Cawthorne). 
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